Digest

IF 1.3 Q4 NEUROSCIENCES

Progress in Neurology and Psychiatry Pub Date : 2021-05-05 DOI:10.1002/pnp.182

K. Gammage, Alyson Crozier, A. Ede, Christopher Hill, S. Locke, Desi McEwan, Kathleen T. Mellano, E. Pila, Matthew Stork, Svenja A. Wolf

引用次数: 0

Abstract

Antidepressant weight gain Anti ‐ depressants are another class of drugs associated with weight gain but a new meta‐analysis of 116 studies identifies some that carry the greatest risk (J Clin Psychiatry 2010;71:1259‐72). Amitriptyline, mirtazapine and paroxetine were associated with the highest risk of weight gain whereas bupropion and acute use of fluoxetine were associated with weight loss. Evidence for other agents was inconclusive.

查看原文本刊更多论文

消化

抗抑郁药体重增加抗抑郁药是另一类与体重增加有关的药物，但一项对116项研究的新荟萃分析确定了一些风险最大的药物（J Clin Psychiatry 2010；71:1259‐72）。阿米替林、米氮平和帕罗西汀与体重增加的最高风险相关，而安非他酮和急性使用氟西汀与体重减轻相关。其他特工的证据没有定论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neurology and Psychiatry NEUROSCIENCES-

CiteScore

1.70

自引率

8.30%

发文量

期刊介绍： Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.